<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ANG</journal-id>
<journal-id journal-id-type="hwp">spang</journal-id>
<journal-id journal-id-type="nlm-ta">Angiology</journal-id>
<journal-title>Angiology</journal-title>
<issn pub-type="ppub">0003-3197</issn>
<issn pub-type="epub">1940-1574</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0003319711425175</article-id>
<article-id pub-id-type="publisher-id">10.1177_0003319711425175</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Peripheral Arterial Disease</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Serum Bilirubin Level is Negatively Correlated With Disease Progression of Peripheral Arterial Disease</article-title>
<subtitle>An Observational Cohort Study</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Hai-Yang</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff1-0003319711425175">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Han</surname>
<given-names>Peng</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff1-0003319711425175">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Zhang</surname>
<given-names>Wei-Hui</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0003319711425175">1</xref>
<xref ref-type="corresp" rid="corresp1-0003319711425175"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Bing</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff1-0003319711425175">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Ha-Li</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-0003319711425175">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Hai-Jun</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff1-0003319711425175">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Ren-Ping</given-names>
</name>
<degrees>MS</degrees>
<xref ref-type="aff" rid="aff1-0003319711425175">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0003319711425175"><label>1</label>Department of General Surgery, the First Affiliated hospital of Harbin Medical University, Harbin, HeiLongjiang, China</aff>
<author-notes>
<corresp id="corresp1-0003319711425175">Wei-Hui Zhang, Department of General Surgery, the First Affiliated hospital of Harbin Medical University, Harbin, HeiLongjiang, China Email: <email>hanpeng88@126.com</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>5</month>
<year>2012</year>
</pub-date>
<volume>63</volume>
<issue>4</issue>
<fpage>248</fpage>
<lpage>253</lpage>
<permissions>
<copyright-statement>© SAGE Publications 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>We determined whether low bilirubin level is a risk factor for peripheral arterial disease (PAD). We recruited 318 patients with PAD and 100 healthy volunteers. Patients were divided into 4 groups by the Fontaine classification for PAD, namely, group 1 (grade 1, n = 4); group 2 (grade 2, n = 114), group 3 (grade 3, n = 164), and group 4 (grade 4, n = 36). Total bilirubin (T-BIL), direct bilirubin (D-BIL), and indirect bilirubin (I-BIL) levels were compared using stepwise multiple regressions adjusted for selected factors. After adjusting for gender, age, smoking, and diastolic blood pressure, serum levels of T-BIL, D-BIL, and I-BIL were significantly lower in the PAD group (<italic>P</italic> &lt; .05). Patients with grade 4 PAD showed significantly (<italic>P</italic> &lt; .05) lower levels of T-BIL when compared with grade 2 patients. We concluded that serum bilirubin levels are negatively correlated with the severity and progression of PAD.</p>
</abstract>
<kwd-group>
<kwd>atherosclerosis</kwd>
<kwd>peripheral arterial disease</kwd>
<kwd>bilirubin</kwd>
<kwd>risk factor</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0003319711425175">
<title>Introduction</title>
<p>Peripheral arterial disease (PAD) is a type of atherosclerotic disease that occurs in the lower extremities and mainly involves moderate sized and large arteries with a multilevel distribution.<sup>
<xref ref-type="bibr" rid="bibr1-0003319711425175">1</xref><xref ref-type="bibr" rid="bibr2-0003319711425175"/>–<xref ref-type="bibr" rid="bibr3-0003319711425175">3</xref>
</sup> The primary risk factors are smoking, hypertension, and elevated levels of cholesterol and glucose.<sup>
<xref ref-type="bibr" rid="bibr1-0003319711425175">1</xref>,<xref ref-type="bibr" rid="bibr2-0003319711425175">2</xref>
</sup> A report from the Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II) in 2007 indicated that 0.6% to 9.2% of the European population displayed intermittent claudication, and of these, 5% to 10% develop severe lower limb ischemia.<sup>
<xref ref-type="bibr" rid="bibr3-0003319711425175">3</xref>
</sup>
</p>
<p>Schwertner et al<sup>
<xref ref-type="bibr" rid="bibr4-0003319711425175">4</xref>
</sup> reported that coronary artery disease (CAD) was negatively correlated with serum bilirubin level. Later in 1994, Breimer et al<sup>
<xref ref-type="bibr" rid="bibr5-0003319711425175">5</xref>
</sup> reported a statistical association between low bilirubin levels and PAD. Similarly, in 2002, Krijgsman et al<sup>
<xref ref-type="bibr" rid="bibr6-0003319711425175">6</xref>
</sup> studied 456 patients classified into those with no clinically evident cardiovascular disease, ischemic heart disease, and PAD and found that low serum bilirubin and albumin levels were associated with the presence of vascular disease. Other prospective, retrospective, and epidemiological studies have reported that increased bilirubin levels are associated with a decreased risk of atherosclerosis and PAD.<sup>
<xref ref-type="bibr" rid="bibr7-0003319711425175">7</xref><xref ref-type="bibr" rid="bibr8-0003319711425175"/><xref ref-type="bibr" rid="bibr9-0003319711425175"/><xref ref-type="bibr" rid="bibr10-0003319711425175"/><xref ref-type="bibr" rid="bibr11-0003319711425175"/><xref ref-type="bibr" rid="bibr12-0003319711425175"/>–<xref ref-type="bibr" rid="bibr13-0003319711425175">13</xref>
</sup> In addition, Ohnaka et al<sup>
<xref ref-type="bibr" rid="bibr14-0003319711425175">14</xref>
</sup> in a study of middle-aged and elderly Japanese participants reported inverse associations of bilirubin with high-sensitivity C-reactive protein, glycated hemoglobin, and the prevalence of type 2 diabetes. Bilirubin has been shown to have an antioxidant effect greater than that of vitamin E.<sup>
<xref ref-type="bibr" rid="bibr9-0003319711425175">9</xref>,<xref ref-type="bibr" rid="bibr15-0003319711425175">15</xref>,<xref ref-type="bibr" rid="bibr16-0003319711425175">16</xref>
</sup> A physiological concentration of bilirubin can effectively scavenge oxygen free radicals, prevent the oxidative modification of low-density lipoproteins (LDLs), and protect vascular endothelial function, thus preventing the occurrence of atherosclerosis.<sup>
<xref ref-type="bibr" rid="bibr9-0003319711425175">9</xref>,<xref ref-type="bibr" rid="bibr16-0003319711425175">16</xref>
</sup>
</p>
<p>In this study, we compared total bilirubin (T-BIL), direct bilirubin (D-BIL), and indirect bilirubin (I-BIL) levels in hospitalized patients with PAD with those of healthy volunteers.</p>
</sec>
<sec id="section2-0003319711425175">
<title>Materials and Methods</title>
<sec id="section3-0003319711425175">
<title>Clinical Data</title>
<p>This observational cohort study included 318 patients with lower extremity PAD (PAD group) who were hospitalized in the First Affiliated Hospital of Harbin Medical University during the period from January 2008 to January 2009 and a normal control group consisting of 100 healthy volunteers who attended an annual checkup at our hospital in 2009. No patients had a history of liver or gallbladder disease, diabetes, serious cardiovascular and cerebrovascular diseases, or rheumatic or immune diseases. As elevated serum bilirubin (both T-BIL and D-BIL) levels are clinically correlated with liver diseases, patients with bile duct obstruction and abnormal bilirubin metabolism with a bilirubin level &gt; 25 µmol/L were excluded. All patients included in the analysis had normal alanine transaminase levels and bilirubin levels within the normal range. The diagnosis of PAD was confirmed by clinical symptoms and signs, ankle–brachial pressure index (ABI) &lt;0.9, and atherosclerotic stenosis or occlusion of the arteries in the lower extremities identified by color Doppler ultrasound, computed tomography angiography (CTA), magnetic resonance angiography (MRA), or digital subtraction angiography (DSA).</p>
<p>All patients were divided into 4 groups according to the Fontaine classification for PAD.<sup>
<xref ref-type="bibr" rid="bibr17-0003319711425175">17</xref>
</sup> Patients were classified based on the limb with the greater grade. Patient data collected included age, gender, smoking status, total cholesterol, high-density lipoprotein (HDL), and LDL levels, body mass index (BMI), systolic blood pressure (SBP), and diastolic blood pressure (DBP). All participants provided written informed consent for the study, and the study protocol was approved by the Institutional Review Board of our hospital.</p>
</sec>
<sec id="section4-0003319711425175">
<title>Determination of Bilirubin Levels</title>
<p>Venous blood samples were collected from all patients in the morning after fasting for 10 hours and stored at room temperature. Serum total bilirubin (T-BIL), D-BIL, and I-BIL levels were measured by the vanadate oxidation method using automatic biochemical analyzer Olympus AU5400 (Olympus America Inc., Melville, NY, USA) within 1 hour after collection. The within-group deviation of vanadate oxidation was &lt;3.0%, the recovery rate range was 95.0% to 105.0%, and the linear range was 0 to 629 µmol/L.<sup>
<xref ref-type="bibr" rid="bibr18-0003319711425175">18</xref>
</sup>
</p>
</sec>
</sec>
<sec id="section5-0003319711425175">
<title>Statistic Analysis</title>
<p>Data were presented as mean ± standard deviation (SD) or percentage (%) and tested with <italic>t</italic> test or chi-square test. Simple linear regression and multivariate regression with stepwise selection were used to evaluate factors associated with D-BIL, I-BIL, and T-BIL levels. Serum bilirubin level with respect to health status and disease stages was compared using multiple regressions adjusted for gender, age, smoking, and DBP with Bonferroni correction for post hoc testing to avoid type I error inflation. Data were analyzed using SPSS 15.0 (SPSS, Inc, Chicago, Illinois). Statistical assessments were 2-tailed and a <italic>P</italic> &lt; .05 was considered significant.</p>
</sec>
<sec id="section6-0003319711425175">
<title>Results</title>
<sec id="section7-0003319711425175">
<title>Patient Characteristics</title>
<p>Characteristics of the PAD and control groups are presented in <xref ref-type="table" rid="table1-0003319711425175">Table 1</xref>
; clinical manifestation of PAD progressed with advance of Fontaine classification grades from 1 to 4. The 318 patients with PAD were categorized according to Fontaine classification grade. The PAD group included 236 males and 82 females with a mean age of 64.2 ± 12 (range, 37-93 years) and the control group consisted of 57 males and 43 females with a mean age of 41.5 ± 10 (range, 22-60 years). In the PAD group, there were 4 grade 1 patients (mean age 67 years) with early stage clinical manifestations of lower limb ischemia. Some patients were symptom free or only had reduced temperature in the lower limbs or occasional muscle spasms. There were 114 grade 2 patients (mean age 65). Patients had intermittent claudication, in which the pain could be relieved by resting and the blood supply to lower extremity could meet the requirement at rest. There were 164 grade 3 patients who had resting pain. Finally, there were 36 grade 4 patients with necrosis and/or gangrene in the lower extremity.</p>
<table-wrap id="table1-0003319711425175" position="float">
<label>Table 1.</label>
<caption>
<p>Patient Characteristics<sup><xref ref-type="table-fn" rid="table-fn2-0003319711425175">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table1-0003319711425175" xlink:href="10.1177_0003319711425175-table1.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">
</th>
<th rowspan="2">Control Group (n = 100)</th>
<th colspan="5">PAD Groups</th>
</tr>
<tr>
<th>Grade 1 (n = 4)</th>
<th>Grade 2 (n = 114)</th>
<th>Grade 3 (n = 164)</th>
<th>Grade 4 (n = 36)</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male</td>
<td>57 (57.0)</td>
<td>1 (25)</td>
<td>85 (74.39)<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>122 (77.78)<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>28 (74.21)<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>.0041</td>
</tr>
<tr>
<td>Age (years)</td>
<td>41.5 ± 10.1</td>
<td>67.50 ± 6.19<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>64.98 ± 11.67<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>64.04 ± 12.63<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>62.39 ± 13.51<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Cholesterol (mmol/L)</td>
<td>4.43 ± 0.54</td>
<td>5.64 ± 0.90<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>4.86 ± 1.07<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>4.93 ± 1.11<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>5.01 ± 1.29<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>.0004</td>
</tr>
<tr>
<td>HDL (mmol/L)</td>
<td>1.16 ± 0.21</td>
<td>1.13 ± 0.29</td>
<td>1.21 ± 0.37</td>
<td>1.16 ± 0.28</td>
<td>1.15 ± 0.20</td>
<td>.69</td>
</tr>
<tr>
<td>LDL (mmol/L)</td>
<td>3.96 ± 4.02</td>
<td>4.10 ± 0.10</td>
<td>3.31 ± 0.97</td>
<td>3.59 ± 0.99</td>
<td>3.62 ± 1.30</td>
<td>.29</td>
</tr>
<tr>
<td>Smoker, n (%)</td>
<td>53 (53.0)</td>
<td>2 (50)</td>
<td>79 (69.3)<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>121 (73.8)<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>35 (97.2)<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref>-<xref ref-type="table-fn" rid="table-fn6-0003319711425175">e</xref></sup>
</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>BMI (kg/m<sup>2</sup>)</td>
<td>21.8 ± 2.4</td>
<td>22.25 ± 1.50</td>
<td>22.34 ± 2.44</td>
<td>22.14 ± 2.18</td>
<td>22.03 ± 1.96</td>
<td>.50</td>
</tr>
<tr>
<td>SBP (mm Hg)</td>
<td>126 ± 11</td>
<td>124 ± 5</td>
<td>132 ± 15</td>
<td>145 ± 15<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref>,<xref ref-type="table-fn" rid="table-fn5-0003319711425175">d</xref></sup>
</td>
<td>151 ± 23<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref>,<xref ref-type="table-fn" rid="table-fn5-0003319711425175">d</xref></sup>
</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>DBP (mm Hg)</td>
<td>82 ± 7</td>
<td>84 ± 5</td>
<td>81 ± 9</td>
<td>93 ± 10<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref>,<xref ref-type="table-fn" rid="table-fn5-0003319711425175">d</xref></sup>
</td>
<td>93 ± 17<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref>-<xref ref-type="table-fn" rid="table-fn5-0003319711425175">d</xref></sup>
</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>D-BIL (µmol/L)</td>
<td>2.42 ± 0.97</td>
<td>1.08 ± 0.79</td>
<td>2.14 ± 1.01</td>
<td>2.21 ± 0.92</td>
<td>2.21 ± 1.21</td>
<td>.036</td>
</tr>
<tr>
<td>I-BIL (µmol/L)</td>
<td>12.37 ± 4.03</td>
<td>9.13 ± 2.62</td>
<td>9.92 ± 2.85<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>9.21 ± 2.86<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>8.45 ± 2.90<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>T-BIL (µmol/L)</td>
<td>14.79 ± 4.77</td>
<td>10.20 ± 3.15</td>
<td>12.07 ± 3.42<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>11.43 ± 3.43<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>10.38 ± 3.94<sup><xref ref-type="table-fn" rid="table-fn3-0003319711425175">b</xref></sup>
</td>
<td>&lt;.0001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0003319711425175">
<p>Abbreviations: PAD, peripheral arterial disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; D-BIL, direct bilirubin; I-BIL, indirect bilirubin; T-BIL, total bilirubin.</p>
</fn>
<fn id="table-fn2-0003319711425175">
<p>
<sup>a</sup> The reference ranges for serum bilirubin levels in the Chinese population are 4.0 to 22.2 µmol/L for T-BIL and 0 to 6 µmol/L for D-BIL. The reference range for total cholesterol level in the Chinese population is 3.9 to 6.5 mmol/L and for LDL level is 1.3 to 4.0 mmol/L. Data are presented as mean ± standard deviation or number (percentage).</p>
</fn>
<fn id="table-fn3-0003319711425175">
<p>
<sup>b</sup> <italic>P</italic> &lt; .05 compared with control, after Bonferroni correction.</p>
</fn>
<fn id="table-fn4-0003319711425175">
<p>
<sup>c</sup> <italic>P</italic> &lt; .05 compared with stage I, after Bonferroni correction.</p>
</fn>
<fn id="table-fn5-0003319711425175">
<p>
<sup>d</sup> <italic>P</italic> &lt; .05 compared with stage II, after Bonferroni correction.</p>
</fn>
<fn id="table-fn6-0003319711425175">
<p>
<sup>e</sup> <italic>P</italic> &lt; .05 compared with stage III, after Bonferroni correction.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>In the PAD group, 74.2% of the participants were male and in the control group 57% were males (<italic>P</italic> = .001). The PAD group contained a higher percentage of smokers compared with the control group (74.5% vs 53.0%, respectively; <italic>P</italic> &lt; .001). Age, total cholesterol level, SBP, and DBP were all significantly greater in the PAD group than in the control group (all <italic>P</italic>s &lt; .05). There were no difference between the 2 groups with respect to HDL and LDL levels and BMI (<italic>P</italic> &gt; .05).</p>
<p>Simple linear regression and multivariate regression with stepwise selection were used to evaluate factors associated with D-BIL, I-BIL, and T-BIL level (<xref ref-type="table" rid="table2-0003319711425175">Table 2</xref>
). Results showed that gender, age, cholesterol level, and DBP were significantly associated with D-BIL level (<italic>R</italic>
<sup>2</sup> = 0.1140, <italic>P</italic> &lt; .0001); gender, age, smoking status, and PAD grade were significantly associated with I-BIL level (<italic>R</italic>
<sup>2</sup> = .1040, <italic>P</italic> &lt; .0001); and gender, age, and PAD grading were significantly associated with T-BIL level (<italic>R</italic>
<sup>2</sup> = .1015, <italic>P</italic> &lt; .0001).</p>
<table-wrap id="table2-0003319711425175" position="float">
<label>Table 2.</label>
<caption>
<p>Results of Univariate and Multivariate Regression With Stepwise Selection Estimating Direct, Indirect, and Total Serum Bilirubin Levels<sup><xref ref-type="table-fn" rid="table-fn8-0003319711425175">a</xref></sup></p>
</caption>
<graphic alternate-form-of="table2-0003319711425175" xlink:href="10.1177_0003319711425175-table2.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Variables</th>
<th colspan="3">Univariate</th>
<th colspan="3">Multivariate</th>
</tr>
<tr>
<th>β</th>
<th>SE (β)</th>
<th>
<italic>P</italic>
</th>
<th>β</th>
<th>SE (β)</th>
<th>
<italic>P</italic>
</th>
</tr>
</thead>
<tbody>
<tr>
<td>D-BIL</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td colspan="2">
<italic>R</italic>
<sup>2</sup> = .1140<sup><xref ref-type="table-fn" rid="table-fn9-0003319711425175">b</xref></sup>
</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td> Male</td>
<td>.418</td>
<td>.125</td>
<td>.0009</td>
<td>.412</td>
<td>.124</td>
<td>.001</td>
</tr>
<tr>
<td> Age</td>
<td>.011</td>
<td>.004</td>
<td>.0163</td>
<td>.014</td>
<td>.004</td>
<td>.0019</td>
</tr>
<tr>
<td> Cholesterol</td>
<td>−.201</td>
<td>.049</td>
<td>&lt;.0001</td>
<td>−.176</td>
<td>.048</td>
<td>.0003</td>
</tr>
<tr>
<td> HDL</td>
<td>−.052</td>
<td>.182</td>
<td>.7731</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> LDL</td>
<td>−.211</td>
<td>.053</td>
<td>&lt;.0001</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Smoke</td>
<td>.035</td>
<td>.128</td>
<td>.7821</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> BMI</td>
<td>.015</td>
<td>.025</td>
<td>.5531</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> SBP</td>
<td>.008</td>
<td>.004</td>
<td>.0605</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> DBP</td>
<td>.007</td>
<td>.003</td>
<td>.0364</td>
<td>.006</td>
<td>.003</td>
<td>.0367</td>
</tr>
<tr>
<td>PAD grade</td>
<td>.096</td>
<td>.083</td>
<td>.2484</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>I-BIL</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td colspan="2">
<italic>R</italic>
<sup>2</sup> = .1040<sup><xref ref-type="table-fn" rid="table-fn9-0003319711425175">b</xref></sup>
</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>
</td>
<td>1.500</td>
<td>.360</td>
<td>&lt;.0001</td>
<td>1.721</td>
<td>.356</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td> Age</td>
<td>.030</td>
<td>.013</td>
<td>.0215</td>
<td>.037</td>
<td>.013</td>
<td>.0034</td>
</tr>
<tr>
<td> Cholesterol</td>
<td>.045</td>
<td>.146</td>
<td>.758</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> HDL</td>
<td>.573</td>
<td>.527</td>
<td>.2783</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> LDL</td>
<td>−.124</td>
<td>.158</td>
<td>.4323</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Smoke</td>
<td>−.436</td>
<td>.371</td>
<td>.2398</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> BMI</td>
<td>.117</td>
<td>.072</td>
<td>.1061</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> SBP</td>
<td>−.015</td>
<td>.013</td>
<td>.2535</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> DBP</td>
<td>−.011</td>
<td>.009</td>
<td>.2512</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>
</td>
<td>−.654</td>
<td>.239</td>
<td>.0065</td>
<td>−.666</td>
<td>.230</td>
<td>.0041</td>
</tr>
<tr>
<td>T-BIL</td>
<td>
</td>
<td>
</td>
<td>
</td>
<td colspan="2">
<italic>R</italic>
<sup>2</sup> = .1015<sup><xref ref-type="table-fn" rid="table-fn9-0003319711425175">b</xref></sup>
</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>
</td>
<td>1.895</td>
<td>.437</td>
<td>&lt;.0001</td>
<td>2.160</td>
<td>.434</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td> Age</td>
<td>.038</td>
<td>.016</td>
<td>.0187</td>
<td>.047</td>
<td>.015</td>
<td>.0024</td>
</tr>
<tr>
<td> Cholesterol</td>
<td>−.239</td>
<td>.177</td>
<td>.1781</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> HDL</td>
<td>.514</td>
<td>.642</td>
<td>.4245</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> LDL</td>
<td>−.420</td>
<td>.191</td>
<td>.0286</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> Smoke</td>
<td>−.435</td>
<td>.451</td>
<td>.3357</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> BMI</td>
<td>.111</td>
<td>.088</td>
<td>.2064</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> SBP</td>
<td>−.006</td>
<td>.016</td>
<td>.7129</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td> DBP</td>
<td>−.002</td>
<td>.011</td>
<td>.8293</td>
<td>
</td>
<td>
</td>
<td>
</td>
</tr>
<tr>
<td>PAD grade</td>
<td>−.647</td>
<td>.292</td>
<td>.0272</td>
<td>−.661</td>
<td>.280</td>
<td>.019</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn7-0003319711425175">
<p>Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein, BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; D-BIL, direct bilirubin; I-BIL, indirect bilirubin; T-BIL, total bilirubin; PAD, peripheral arterial disease; β, parameter estimate; SE (β), standard error of the parameter estimate.</p>
</fn>
<fn id="table-fn8-0003319711425175">
<p>
<sup>a</sup> <italic>P</italic> &lt; .05 indicates significant difference.</p>
</fn>
<fn id="table-fn9-0003319711425175">
<p>
<sup>b</sup> <italic>R</italic>
<sup>2</sup> of the multivariate regression model.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section8-0003319711425175">
<title>Bilirubin Levels in the PAD Group and the Control Group</title>
<p>Since significant differences were found between the PAD and control groups for the association of some variables and individual serum bilirubin levels, differences in D-BIL level between the PAD and control group were examined after adjusting for gender and cholesterol. As shown in <xref ref-type="fig" rid="fig1-0003319711425175">Figure 1</xref>
, a significantly lower serum level of D-BIL was found in the PAD group compared with the control group after adjustment (<italic>P</italic> &lt; .05). In addition, gender, age, smoking status, and DBP were adjusted before comparing D-BIL and T-BIL levels between the PAD and control group. After adjusting for these variables, significantly lower serum levels of I-BIL and T-BIL were found in the PAD group compared with the control group (<italic>P</italic> &lt; .05).</p>
<fig id="fig1-0003319711425175" position="float">
<label>Figure 1.</label>
<caption>
<p>Direct serum bilirubin and total serum bilirubin levels of the peripheral arterial disease and control groups adjusted for gender, age, smoking status, and diastolic blood pressure. Data are mean ± standard deviation. *<italic>P</italic> &lt; .05 indicates a significant difference.</p>
</caption>
<graphic xlink:href="10.1177_0003319711425175-fig1.tif"/>
</fig>
</sec>
<sec id="section9-0003319711425175">
<title>Bilirubin Levels Based on PAD Grade</title>
<p>
<xref ref-type="fig" rid="fig2-0003319711425175">Figure 2</xref>
shows T-BIL, D-BIL, and I-BIL levels in patients with PAD by disease stage adjusted for variables significantly associated with individual bilirubin level as shown in <xref ref-type="fig" rid="fig1-0003319711425175">Figure 1</xref>. The levels of D-BIL and I-BIL were not significantly different among the 4 groups (<italic>P</italic> &gt; .05). The level of T-BIL was significantly lower in patients with grade 4 disease than for those with grade 2 disease (<italic>P</italic> &lt; .05).</p>
<fig id="fig2-0003319711425175" position="float">
<label>Figure 2.</label>
<caption>
<p>Direct serum bilirubin levels of patients with PAD by disease stage adjusted for gender and total cholesterol; indirect serum bilirubin and total serum bilirubin levels of patients with PAD by disease stage adjusted for gender, age, smoking status, and diastolic blood pressure. Data are mean ± standard deviation. *<italic>P</italic> &lt; .05 indicates a significant difference. PAD indicates peripheral arterial disease.</p>
</caption>
<graphic xlink:href="10.1177_0003319711425175-fig2.tif"/>
</fig>
</sec>
</sec>
<sec id="section10-0003319711425175">
<title>Discussion</title>
<p>In this study, there were significant differences between the PAD and control groups with respect to age, gender, percentage of smokers, total cholesterol, and DBP. However, after adjusting for these parameters, the serum levels of T-BIL, D-BIL, and I-BIL were significantly lower in patients with PAD than those in normal controls. In addition, the serum T-BIL level in patients with PAD grade 4 was significantly lower than those with PAD grade 2, suggesting that serum bilirubin levels are negatively correlated with PAD grade. This study was, however, a case-controlled study, which demonstrated association but not causation.</p>
<p>Arterial stenosis due to an atherosclerotic and rough arterial intima may possibly result in the damage of red blood cells, leading to an increase in serum bilirubin level since bilirubin is the breakdown product of heme found in hemoglobin, a principal component of red blood cells. The patients with PAD, in this study, did not have any relevant diseases that can reduce the serum bilirubin level.</p>
<p>Since the report in 1994 by Schwertner et al,<sup>
<xref ref-type="bibr" rid="bibr4-0003319711425175">4</xref>
</sup> which indicated CAD was negatively correlated with serum bilirubin level, and a low concentration of serum bilirubin was an independent risk factor for CAD, numerous studies have confirmed the findings and low bilirubin is now considered a risk factor for CAD. A meta-analysis<sup>
<xref ref-type="bibr" rid="bibr7-0003319711425175">7</xref>
</sup> found an “unambiguous” inverse relationship between serum bilirubin levels and atherosclerosis. Vítek et al<sup>
<xref ref-type="bibr" rid="bibr8-0003319711425175">8</xref>
</sup> showed an inverse association of elevated serum bilirubin with subclinical carotid atherosclerosis in healthy men. Recently, results of the Prospective Epidemiological Study of Myocardial infarction (PRIME) study by Troughton et al<sup>
<xref ref-type="bibr" rid="bibr13-0003319711425175">13</xref>
</sup> showed that bilirubin level may be a marker of coronary heart disease in middle-aged men. In addition, Gullu et al<sup>
<xref ref-type="bibr" rid="bibr17-0003319711425175">17</xref>
</sup> showed that high bilirubin levels preserve coronary flow reserve and microvascular functions. While it has become clear that decreased levels of bilirubin are associated with atherosclerotic disease, the cause of decreased bilirubin levels is yet to be determined.</p>
<p>The gene <italic>UGT1A1</italic> is important in controlling bilirubin metabolism, and a number of studies have suggested an association between gene variants, bilirubin levels, and cardiovascular disease.<sup>
<xref ref-type="bibr" rid="bibr11-0003319711425175">11</xref>,<xref ref-type="bibr" rid="bibr12-0003319711425175">12</xref>,<xref ref-type="bibr" rid="bibr18-0003319711425175">18</xref><xref ref-type="bibr" rid="bibr19-0003319711425175"/><xref ref-type="bibr" rid="bibr20-0003319711425175"/><xref ref-type="bibr" rid="bibr21-0003319711425175"/><xref ref-type="bibr" rid="bibr22-0003319711425175"/>–<xref ref-type="bibr" rid="bibr23-0003319711425175">23</xref>
</sup> However, it is still unclear whether there is a causal relationship among the variables. In a prospective nested case-referent study, Ekblom et al<sup>
<xref ref-type="bibr" rid="bibr24-0003319711425175">24</xref>
</sup> examined the relationship between bilirubin, the UGT1A1*28 polymorphism, and ischemic stroke and concluded that there was no evidence for a protective effect of the polymorphism, and thus bilirubin, for ischemic stroke. Additionally, in a similar study, Ekblom et al<sup>
<xref ref-type="bibr" rid="bibr25-0003319711425175">25</xref>
</sup> reported that bilirubin and the UGT1A1*28 polymorphism were not protective factors against first-time myocardial infarction.</p>
<p>The protective effect of bilirubin may be due, at least in part, to its antioxidant properties.<sup>
<xref ref-type="bibr" rid="bibr15-0003319711425175">15</xref>
</sup> Bilirubin has stronger antioxidant activity than vitamin C, vitamin E, and β-carotene.<sup>
<xref ref-type="bibr" rid="bibr8-0003319711425175">8</xref>,<xref ref-type="bibr" rid="bibr15-0003319711425175">15</xref>,<xref ref-type="bibr" rid="bibr16-0003319711425175">16</xref>
</sup> It has also been demonstrated that bilirubin can inhibit vascular smooth muscle cell proliferation following damage caused by balloon expansion.<sup>
<xref ref-type="bibr" rid="bibr21-0003319711425175">21</xref>
</sup> Thus, a normal bilirubin level may play a critical role in the prevention of atherosclerosis.<sup>
<xref ref-type="bibr" rid="bibr1-0003319711425175">1</xref>,<xref ref-type="bibr" rid="bibr7-0003319711425175">7</xref>,<xref ref-type="bibr" rid="bibr9-0003319711425175">9</xref>
</sup> There are a number of mechanisms by which bilirubin may inhibit the development and progression of atherosclerosis, such as scavenging oxygen free radicals and preventing lipid oxidation,<sup>
<xref ref-type="bibr" rid="bibr15-0003319711425175">15</xref>
</sup> promoting lipid dissolution and bile excretion,<sup>
<xref ref-type="bibr" rid="bibr4-0003319711425175">4</xref>
</sup> suppressing the immune response and inflammation,<sup>
<xref ref-type="bibr" rid="bibr23-0003319711425175">23</xref>,<xref ref-type="bibr" rid="bibr24-0003319711425175">24</xref>,<xref ref-type="bibr" rid="bibr26-0003319711425175">26</xref>,<xref ref-type="bibr" rid="bibr27-0003319711425175">27</xref>
</sup> and inhibiting protein kinase C activity<sup>
<xref ref-type="bibr" rid="bibr28-0003319711425175">28</xref>
</sup> and p38 protein phosphorylation.<sup>
<xref ref-type="bibr" rid="bibr29-0003319711425175">29</xref>
</sup>
</p>
<p>The activity of bilirubin is primarily regulated by heme oxygenase (HO), which is a rate-limiting enzyme for heme catabolism. Poss and Tonegawa<sup>
<xref ref-type="bibr" rid="bibr26-0003319711425175">26</xref>
</sup> showed that the production of bilirubin stimulated by increased HO-1 gene expression is an adaptive mechanism to protect cells from oxidative damage during a stress response. Increased HO-1 expression can promote angiogenesis, protect cells from damage due to toxic compounds, and protect against oxidants such as H<sub>2</sub>O<sub>2</sub>.<sup>
<xref ref-type="bibr" rid="bibr27-0003319711425175">27</xref>,<xref ref-type="bibr" rid="bibr28-0003319711425175">28</xref>
</sup>
</p>
<p>While our results did indicate a statistically significant difference in bilirubin levels between the PAD group and normal controls, only a difference in T-BIL levels was found between patients with grades 2 and 4 diseases. This finding is somewhat different from that of a meta-analysis by Novotný and Vítek<sup>
<xref ref-type="bibr" rid="bibr7-0003319711425175">7</xref>
</sup> that found a linear relationship between serum bilirubin level and atherosclerosis in men. This could be attributed to a number of reasons. The number of patients with grades 1 and 4 diseases was relatively small, making it difficult to obtain a significant difference. Patients with grade 1 disease have relatively mild or no symptoms and are less likely to seek medical attention. In addition, early-stage PAD may be misdiagnosed. With respect to grades 2 and 3 diseases, there is a certain degree of subjectivity involved for self-described disease and in distinguishing the 2 grades, thus there could be patient overlap between the 2 groups that would mask the difference in the bilirubin levels.</p>
<p>In this study, age matching was not performed. However, in separate analyses (data on file), when cases and controls were combined, age was not associated with differences in bilirubin levels; when age-matched controls and cases were analyzed serum bilirubin was found to be significantly lower in cases compared to age-matched controls; when bilirubin levels were examined both in in males and females, in the age groups of 60 to 70 and older than 70, which contained case participants only, significant differences in serum bilirubin between genders was noted, that is, bilirubin levels in women were significantly lower than that in men; and finally, in the analyses of matched male controls and male participants with PAD and the same analysis of female participants with PAD, the results showed that T-BIL levels were significantly decreased in cases compared with controls in the age-matched groups. Thus, although age matching was not performed, we believe that the results are accurate and reflect an inverse relationship between bilirubin and PAD.</p>
<p>Some limitations of this study should be considered. First, as mentioned previously, the number of patients with different grades of PAD was relatively small, especially those with grades 1 and 4 diseases. Grade of PAD was primarily based on the patients' description of their symptoms, while other tests were only used to confirm the presence of PAD. This may have resulted in inaccuracies in the grading of PAD. These factors may have contributed to only finding a significant difference in bilirubin levels in the groups with grades 2 and 4 diseases. In addition, bilirubin level was only measured at a single time point for each patient. Finally, the control group was significantly younger than the PAD group. Age was controlled for in our analysis, and although age may have some impact, no specific study has shown that age is an independent risk factor for bilirubin reduction. Our screening criteria may have failed to exclude patients with subclinical hepatitis. It is possible that these patients were included; however, their tests of liver function and bilirubin levels were normal and thus the impact on the results would be small or insignificant.</p>
<p>In conclusion, the results of this study indicate a correlation between bilirubin levels and PAD, and serum T-BIL level decreased with increasing severity of PAD. These results confirm other reports that elevated bilirubin levels offer a protective effect against atherosclerotic diseases. Determination of a correlation between PAD grade and bilirubin level may assist in early diagnosis and treatment. Further in vivo studies investigating the mechanisms underlying decreased bilirubin in patients with PAD and protection against PAD may assist in developing new targets for prevention and treatment.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict" id="fn1-0003319711425175">
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn2-0003319711425175">
<p>The authors received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0003319711425175">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fujiwara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Saitoh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Takagi</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Prevalence of asymptomatic arteriosclerosis obliterans and its relationship with risk factors in inhabitants of rural communities in Japan: Tanno-Sobetsu study</article-title>. <source>Atherosclerosis</source>. <year>2004</year>;<volume>177</volume>(<issue>1</issue>):<fpage>83</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr2-0003319711425175">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mutirangura</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Ruangsetakit</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wongwanit</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sermsathanasawadi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Chinsakchai</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Atherosclerosis obliterans of the lower extremities in Thai patients</article-title>. <source>J Med Assoc Thai</source>. <year>2006</year>;<volume>89</volume>(<issue>10</issue>):<fpage>1612</fpage>–<lpage>1620</lpage>.</citation>
</ref>
<ref id="bibr3-0003319711425175">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author"><name><surname>Norgren</surname><given-names>L</given-names></name><name><surname>Hiatt</surname><given-names>WR</given-names></name><name><surname>Dormandy</surname><given-names>JA</given-names></name><name><surname>Nehler</surname><given-names>MR</given-names></name><name><surname>Harris</surname><given-names>KA</given-names></name><name><surname>Fowkes</surname><given-names>FG</given-names></name><name><surname>Rutherford</surname><given-names>RB</given-names></name></person-group>; <collab collab-type="author">TASC II Working Group</collab>. <article-title>Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)</article-title>. <source>Int Angiol.</source> <year>2007</year>;<volume>26</volume>(<issue>2</issue>):<fpage>81</fpage>-<lpage>157</lpage>. <comment>Review</comment>.
</citation>
</ref>
<ref id="bibr4-0003319711425175">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwertner</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>WG</given-names>
</name>
<name>
<surname>Tolan</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Association of low serum concentration of bilirubin with increased risk of coronary artery disease</article-title>. <source>Clin Chem</source>. <year>1994</year>;<volume>40</volume>(<issue>1</issue>):<fpage>18</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr5-0003319711425175">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breimer</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Spyropolous</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Winder</surname>
<given-names>AF</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Is bilirubin protective against coronary artery disease?</article-title> <source>Clin Chem</source>. <year>1994</year>;<volume>40</volume>(<issue>10</issue>):<fpage>1987</fpage>–<lpage>1988</lpage>.</citation>
</ref>
<ref id="bibr6-0003319711425175">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Krijgsman</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Papadakis</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Ganotakis</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
<name>
<surname>Hamilton</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>The effect of peripheral vascular disease on the serum levels of natural anti-oxidants: bilirubin and albumin</article-title>. <source>Int Angiol</source>. <year>2002</year>;<volume>21</volume>(<issue>1</issue>):<fpage>44</fpage>–<lpage>52</lpage>.</citation>
</ref>
<ref id="bibr7-0003319711425175">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Novotný</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vítek</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies</article-title>. <source>Exp Biol Med (Maywood)</source>. <year>2003</year>;<volume>228</volume>(<issue>5</issue>):<fpage>568</fpage>–<lpage>571</lpage>.</citation>
</ref>
<ref id="bibr8-0003319711425175">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vítek</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Novotný</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Sperl</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Holaj</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Spácil</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>The inverse association of elevated serum bilirubin levels with subclinical carotid atherosclerosis</article-title>. <source>Cerebrovasc Dis</source>. <year>2006</year>;<volume>21</volume>(<issue>5-6</issue>):<fpage>408</fpage>–<lpage>414</lpage>.</citation>
</ref>
<ref id="bibr9-0003319711425175">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perlstein</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Pande</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Beckman</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Creager</surname>
<given-names>MA</given-names>
</name>
</person-group>. <article-title>Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2008</year>;<volume>28</volume>(<issue>1</issue>):<fpage>166</fpage>–<lpage>172</lpage>.</citation>
</ref>
<ref id="bibr10-0003319711425175">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hunt</surname>
<given-names>SC</given-names>
</name>
<name>
<surname>Kronenberg</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Eckfeldt</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Hopkins</surname>
<given-names>PN</given-names>
</name>
<name>
<surname>Myers</surname>
<given-names>RH</given-names>
</name>
<name>
<surname>Heiss</surname>
<given-names>G</given-names>
</name>
</person-group>. <article-title>Association of plasma bilirubin with coronary heart disease and segregation of bilirubin as a major gene trait: the NHLBI family heart study</article-title>. <source>Atherosclerosis</source>. <year>2001</year>;<volume>154</volume>(<issue>3</issue>):<fpage>747</fpage>–<lpage>754</lpage>.</citation>
</ref>
<ref id="bibr11-0003319711425175">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rantner</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Kollerits</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Anderwald-Stadler</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>. <article-title>Association between the UGT1A1 TA-repeat polymorphism and bilirubin concentration in patients with intermittent claudication: results from the CAVASIC study</article-title>. <source>Clin Chem</source>. <year>2008</year>;<volume>54</volume>(<issue>5</issue>):<fpage>851</fpage>–<lpage>857</lpage>.</citation>
</ref>
<ref id="bibr12-0003319711425175">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwertner</surname>
<given-names>HA</given-names>
</name>
<name>
<surname>Vítek</surname>
<given-names>L</given-names>
</name>
</person-group>. <article-title>Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin</article-title>. <source>Atherosclerosis</source>. <year>2008</year>;<volume>198</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>11</lpage>.</citation>
</ref>
<ref id="bibr13-0003319711425175">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Troughton</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Woodside</surname>
<given-names>JV</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>IS</given-names>
</name>
<etal/>
</person-group>. <article-title>PRIME Study Group. Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME)</article-title>. <source>Eur J Cardiovasc Prev Rehabil</source>. <year>2007</year>;<volume>14</volume>(<issue>1</issue>):<fpage>79</fpage>–<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr14-0003319711425175">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohnaka</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kono</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Inoguchi</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Inverse associations of serum bilirubin with high sensitivity C-reactive protein, glycated hemoglobin, and prevalence of type 2 diabetes in middle-aged and elderly Japanese men and women</article-title>. <source>Diabetes Res Clin Pract</source>. <year>2010</year>;<volume>88</volume>(<issue>1</issue>):<fpage>103</fpage>–<lpage>110</lpage>.</citation>
</ref>
<ref id="bibr15-0003319711425175">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>TW</given-names>
</name>
<name>
<surname>Fung</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Weisel</surname>
<given-names>RD</given-names>
</name>
</person-group>. <article-title>Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins</article-title>. <source>Biochem Pharmacol</source>. <year>1996</year>;<volume>51</volume>(<issue>6</issue>):<fpage>859</fpage>–<lpage>862</lpage>.</citation>
</ref>
<ref id="bibr16-0003319711425175">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>YT</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>JH</given-names>
</name>
</person-group>. <article-title>The relationship between bilirubin and oxygen free radicals and cardiovascular diseases</article-title>. <source>Chin J Arteriosclerosis</source>. <year>2006</year>;<volume>14</volume>:<fpage>53</fpage>–<lpage>56</lpage>.</citation>
</ref>
<ref id="bibr17-0003319711425175">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gullu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Erdogan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Tok</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>. <article-title>High serum bilirubin concentrations preserve coronary flow reserve and coronary microvascular functions</article-title>. <source>Arterioscler Thromb Vasc Biol</source>. <year>2005</year>;<volume>25</volume>(<issue>11</issue>):<fpage>2289</fpage>–<lpage>2294</lpage>.</citation>
</ref>
<ref id="bibr18-0003319711425175">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lingenhel</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Kollerits</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Schwaiger</surname>
<given-names>JP</given-names>
</name>
<etal/>
</person-group>. <article-title>Serum bilirubin levels, UGT1A1 polymorphisms and risk for coronary artery disease</article-title>. <source>Exp Gerontol</source>. <year>2008</year>;<volume>43</volume>(<issue>12</issue>):<fpage>1102</fpage>–<lpage>1107</lpage>.</citation>
</ref>
<ref id="bibr19-0003319711425175">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Suematsu</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ishimura</surname>
<given-names>Y</given-names>
</name>
</person-group>. <article-title>The heme oxygenase-carbon monoxide system: a regulator of hepatobiliary function</article-title>. <source>Hepatology</source>. <year>2000</year>;<volume>31</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr20-0003319711425175">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Breimer</surname>
<given-names>LH</given-names>
</name>
<name>
<surname>Mikhailidis</surname>
<given-names>DP</given-names>
</name>
</person-group>. <article-title>Could carbon monoxide and bilirubin be friends as well as foes of the body?</article-title> <source>Scand J Clin Lab Invest</source>. <year>2010</year>;<volume>70</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr21-0003319711425175">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ollinger</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Bilban</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Erat</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Bilirubin: a natural inhibitor of vascular smooth muscle cell proliferation</article-title>. <source>Circulation</source>. <year>2005</year>;<volume>112</volume>(<issue>7</issue>):<fpage>1030</fpage>–<lpage>1039</lpage>.</citation>
</ref>
<ref id="bibr22-0003319711425175">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vicente</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Guillin</surname>
<given-names>MI</given-names>
</name>
<name>
<surname>Alcaraz</surname>
<given-names>MJ</given-names>
</name>
</person-group>. <article-title>Participation of heme oxygenase-1 in a model of acute inflammation</article-title>. <source>Exp Biol Med (Maywood)</source>. <year>2003</year>;<volume>228</volume>(<issue>5</issue>):<fpage>514</fpage>–<lpage>516</lpage>.</citation>
</ref>
<ref id="bibr23-0003319711425175">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Paine</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Eiz-Vesper</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Blasczyk</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Immenschuh</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Signaling to heme oxygenase-1 and its anti-inflammatory therapeutic potential</article-title>. <source>Biochem Pharmacol</source>. <year>2010</year>;<volume>80</volume>(<issue>12</issue>):<fpage>1895</fpage>–<lpage>1803</lpage>.</citation>
</ref>
<ref id="bibr24-0003319711425175">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ekblom</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Marklund</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Johansson</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Bilirubin and UGT1A1*28 are not associated with lower risk for ischemic stroke in a prospective nested case-referent setting</article-title>. <source>Cerebrovasc Dis</source>. <year>2010</year>;<volume>30</volume>(<issue>6</issue>):<fpage>590</fpage>–<lpage>596</lpage>.</citation>
</ref>
<ref id="bibr25-0003319711425175">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ekblom</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Marklund</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Jansson</surname>
<given-names>JH</given-names>
</name>
<etal/>
</person-group>. <article-title>Plasma bilirubin and UGT1A1*28 are not protective factors against first-time myocardial infarction in a prospective, nested case-referent setting</article-title>. <source>Circ Cardiovasc Genet</source>. <year>2010</year>;<volume>3</volume>(<issue>4</issue>):<fpage>340</fpage>–<lpage>347</lpage>.</citation>
</ref>
<ref id="bibr26-0003319711425175">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Poss</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Tonegawa</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Reduced stress defense in heme oxygenase 1-deficient cells</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1997</year>;<volume>94</volume>(<issue>20</issue>):<fpage>10925</fpage>–<lpage>10930</lpage>.</citation>
</ref>
<ref id="bibr27-0003319711425175">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nakayama</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Komaru</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Increased expression of heme oxygenase l and bilirubin accumulation in foam cells of rabbit atherosclerotic lesions</article-title>. <source>Arteroscler Thromb Vasc Biol</source>. <year>2001</year>;<volume>21</volume>(<issue>8</issue>):<fpage>1373</fpage>–<lpage>1377</lpage>.</citation>
</ref>
<ref id="bibr28-0003319711425175">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Amit</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Boneh</surname>
<given-names>A</given-names>
</name>
</person-group>. <article-title>Bilirubin inhibits protein kinase C activity and protein kinase C-mediated phosphorylation of endogenous substrates in human skin fibroblasts</article-title>. <source>Clin Chim Acta</source>. <year>1993</year>;<volume>223</volume>(<issue>1-2</issue>):<fpage>103</fpage>–<lpage>111</lpage>.</citation>
</ref>
<ref id="bibr29-0003319711425175">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zou</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Homocysteine enhances cell proliferation in vascular smooth muscle cells: role of p38 MAPK and p47phox</article-title>. <source>Acta Biochim Biophys Sin (Shanghai)</source>. <year>2010</year>;<volume>42</volume>(<issue>12</issue>):<fpage>908</fpage>–<lpage>915</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>